H. Dundar Et Al. , "Combination of the histone deacetylase inhibitor valproic acid and stopcodon readthrough therapy produces improved alpha-galactosidase activity in Fabry patient-derived R227X fibroblasts," EUROPEAN JOURNAL OF HUMAN GENETICS , vol.30, no.SUPPL 1, pp.558, 2022
Dundar, H. Et Al. 2022. Combination of the histone deacetylase inhibitor valproic acid and stopcodon readthrough therapy produces improved alpha-galactosidase activity in Fabry patient-derived R227X fibroblasts. EUROPEAN JOURNAL OF HUMAN GENETICS , vol.30, no.SUPPL 1 , 558.
Dundar, H., BİBEROĞLU, G., İNCİ, A., OKUR, İ., Tumer, L., & Ezgu, F., (2022). Combination of the histone deacetylase inhibitor valproic acid and stopcodon readthrough therapy produces improved alpha-galactosidase activity in Fabry patient-derived R227X fibroblasts. EUROPEAN JOURNAL OF HUMAN GENETICS , vol.30, no.SUPPL 1, 558.
Dundar, HALİL Et Al. "Combination of the histone deacetylase inhibitor valproic acid and stopcodon readthrough therapy produces improved alpha-galactosidase activity in Fabry patient-derived R227X fibroblasts," EUROPEAN JOURNAL OF HUMAN GENETICS , vol.30, no.SUPPL 1, 558, 2022
Dundar, HALİL Et Al. "Combination of the histone deacetylase inhibitor valproic acid and stopcodon readthrough therapy produces improved alpha-galactosidase activity in Fabry patient-derived R227X fibroblasts." EUROPEAN JOURNAL OF HUMAN GENETICS , vol.30, no.SUPPL 1, pp.558, 2022
Dundar, H. Et Al. (2022) . "Combination of the histone deacetylase inhibitor valproic acid and stopcodon readthrough therapy produces improved alpha-galactosidase activity in Fabry patient-derived R227X fibroblasts." EUROPEAN JOURNAL OF HUMAN GENETICS , vol.30, no.SUPPL 1, p.558.
@article{article, author={HALİL DÜNDAR Et Al. }, title={Combination of the histone deacetylase inhibitor valproic acid and stopcodon readthrough therapy produces improved alpha-galactosidase activity in Fabry patient-derived R227X fibroblasts}, journal={EUROPEAN JOURNAL OF HUMAN GENETICS}, year=2022, pages={558} }